The launch in Japan opens a new revenue stream for Joenja, particularly in the pediatric segment (ages 4-11) where it is first-to-market globally. Monitor future quarterly filings for initial Japan sales data and potential label expansion in other countries for pediatric patients.
Price Chart
Executive Summary
Pharming Group announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4 and older, following NHI drug price list inclusion. This is the first market where Joenja is available for children aged 4-11, expanding the addressable pediatric patient population and marking a key milestone in global commercialization.
Key Facts
- Joenja launched commercially in Japan for APDS patients aged 4+ after NHI price list inclusion
- Japan is the first market where Joenja is available for children aged 4-11
- OrphanPacific is Marketing Authorization Holder and handles supply/distribution in Japan
- Approval by Japan's MHLW occurred in March 2026
- APDS affects approximately 1-2 people per million worldwide
Financial Impact
Not disclosed in the press release; no revenue or deal value provided.
Risk Factors
- Japan market revenue contribution may be modest given ultra-rare disease prevalence (1-2 per million)
- Dependence on OrphanPacific for supply and distribution introduces operational risk
- No financial terms of the OrphanPacific agreement disclosed
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344210 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers